Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary

Incidence of low grade well-differentiated neuroendocrine tumors (NET) is on the rise. The North American Neuroendocrine Tumor Society estimates that the United States has more than 150,000 gastroenteropancreatic NET patients. About 10% of metastatic NETs can be unknown primary, and due to their rar...

Full description

Bibliographic Details
Main Authors: Aman Chauhan, Zainab Farooqui, Le Aundra Murray, Heidi L. Weiss, Zin War Myint, Arun Kumar A. Raajasekar, B. Mark Evers, Susanne Arnold, Lowell Anthony
Format: Article
Language:English
Published: Hindawi Limited 2018-01-01
Series:Journal of Oncology
Online Access:http://dx.doi.org/10.1155/2018/3519247

Internet

http://dx.doi.org/10.1155/2018/3519247

Similar Items